Marshall Wace LLP Buys Shares of 438,806 Tempus AI, Inc. (NASDAQ:TEM)

Marshall Wace LLP acquired a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 438,806 shares of the company's stock, valued at approximately $14,814,000. Marshall Wace LLP owned 0.28% of Tempus AI at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Stifel Financial Corp purchased a new position in Tempus AI during the third quarter worth approximately $218,000. Geode Capital Management LLC increased its holdings in shares of Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company's stock worth $7,537,000 after buying an additional 539 shares during the last quarter. Tidal Investments LLC purchased a new position in shares of Tempus AI in the 3rd quarter worth $7,633,000. Franklin Resources Inc. boosted its holdings in Tempus AI by 1.0% in the third quarter. Franklin Resources Inc. now owns 811,311 shares of the company's stock valued at $45,920,000 after acquiring an additional 8,387 shares during the last quarter. Finally, Silverleafe Capital Partners LLC acquired a new position in Tempus AI in the fourth quarter valued at $533,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of research reports. Wolfe Research downgraded Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. TD Cowen reissued a "buy" rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. William Blair restated a "market perform" rating on shares of Tempus AI in a report on Tuesday, February 25th. JPMorgan Chase & Co. downgraded Tempus AI from an "overweight" rating to a "neutral" rating and increased their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Finally, Guggenheim restated a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $61.08.

Tempus AI Trading Up 8.0 %

NASDAQ:TEM traded up $3.95 during mid-day trading on Thursday, reaching $53.50. The stock had a trading volume of 10,443,087 shares, compared to its average volume of 5,633,943. The stock's 50 day simple moving average is $50.50 and its two-hundred day simple moving average is $50.40. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Transactions at Tempus AI

In related news, Director Wayne A.I. Frederick sold 3,000 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $45.54, for a total transaction of $136,620.00. Following the sale, the director now owns 26,514 shares in the company, valued at $1,207,447.56. This represents a 10.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric P. Lefkofsky sold 85,788 shares of the firm's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the completion of the transaction, the chief executive officer now directly owns 5,771,787 shares in the company, valued at $308,155,707.93. This represents a 1.46 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,670,040 shares of company stock worth $277,450,802.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.